All In Biotech

Drug Trial Radar · NCT03335072

Kebele Elimination of Trachoma for Ocular Health

Last checked: Nov 19, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 320,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

320,000

Planned (sponsor's estimate)

Start

Feb 7, 2022

Primary completion

Mar 1, 2027

Study completion Mar 1, 2028

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Eye Institute (NEI); Eyu-Ethiopia; Bahir Dar University
First posted
Nov 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution.

Conditions

  • Trachoma

Interventions

  • AzithromycinDrug

    Mass Drug Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular chlamydia measured in a population based age-stratified sample of the entire communityTime frame: 36 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • UCSF Proctor Foundation

    San Francisco, California

  • Eyu-Ethiopia

    Bahir Dar, Ethiopia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.